quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2....
HR+和HR-eBC中,HER2 低表达和HER2零表达患者比例不同,其中在 HR+乳腺癌中,171例(61%)为HER2低表达患者,HR-乳腺癌中,HER2低表达患者65例(28%)。 图1 本研究的 CONSORT 图 当分别在HR+和HR-肿瘤中比较HER2-low和 HER2-0肿瘤...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
e13030#Background:IHC/FISH is currently the gold standard method of HER2 expression assessment on breast cancer (BC) cells. Recent studies regarding HER2-low category show that the semi-quantitative methods are inaccurate. False-negative results may have a negative impact on the prognosis and ...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
That means 18% of Her2 negative results will transform into a Her2 positive status and will have the affinity to spread to the central nervous system (CNS). With the identification of CD44, CD24, and ALDH1, we may be able to determine which group of triple negative breast cancer patients...
aAmong triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results. 在三倍消极乳腺癌之中, HER2( 0) 乳腺癌显示一个强的倾向是基础象比较HER2( 1+) 乳腺癌: 初步结果。[translate]...
Matetrials and Methods Breast cancer cell lines. Two breast cancer cell lines over-expressing different levels of HER2 receptors were chosen for this study: BT474 and SK-BR-3. We used MDA-MB-231 breast cancer cell line as the HER2-negative control group. The immortalized mammary ...